NEWARK, Calif.
加利福尼亚州纽瓦克
,
，
May 12, 2026
2026年5月12日
/PRNewswire/ -- ATUM, a global leader in bioengineering and cell line development, today announced the official launch of its
/PRNewswire/ -- ATUM，一家全球领先的生物工程和细胞系开发公司，今天正式宣布推出其
Lock-In™ Bispecifics Platform
锁定™双特异性平台
. Debuting at the PEGS Boston Summit, the platform is engineered to address the most critical hurdles in bispecific antibody (bsAb) development: complex molecular design requirements, light-chain mispairing, and biophysical instability.
在PEGS波士顿峰会上首次亮相的该平台，旨在解决双特异性抗体（bsAb）开发中最关键的障碍：复杂的分子设计需求、轻链错配以及生物物理不稳定性。
The IgG-Like Advantage: Superior Developability by Design
IgG样优势：通过设计实现卓越的可开发性
Traditional bispecific formats often require 'non-natural' structural compromises that result in increased aggregation, reduced stability, and expression difficulties. ATUM's
传统的双特异性格式通常需要“非天然”的结构妥协，这会导致聚集增加、稳定性降低以及表达困难。ATUM的
Lock-In™ platform
锁定平台
solves these challenges by utilizing a robust
通过利用强大的工具解决了这些挑战
IgG-like architecture
IgG样结构
. By mimicking the natural symmetry and stability of standard monoclonal antibodies, the platform provides:
通过模仿天然的对称性和标准单克隆抗体的稳定性，该平台提供：
Minimized Aggregation:
最小化聚合：
Unlike fragment-based bispecifics that expose 'sticky' hydrophobic patches, the Lock-In™ IgG-like scaffold protects the molecular interface, drastically reducing the risk of aggregation and immunogenicity.
与暴露“粘性”疏水区域的片段型双特异性抗体不同，Lock-In™ IgG样支架保护了分子界面，大幅降低了聚集和免疫原性的风险。
Increased Stability:
更高的稳定性：
By minimizing structural changes, the molecule is expected to perform in manners similar to IgG molecules, including clearance, solubility, and viscosity.
通过最小化结构变化，该分子预计将以类似于 IgG 分子的方式发挥作用，包括清除率、溶解度和粘度。
Improved Expression:
改进的表达式：
By retaining the full Fc region, Lock-In™ molecule expression and purification will align closer to IgG conditions, reducing the need to develop novel manufacturing capabilities or processes.
通过保留完整的Fc区域，Lock-In™分子的表达和纯化将更接近于IgG条件，减少了开发新的生产能力或工艺的需求。
Bridging the Gap: From Discovery to Development
弥合差距：从发现到发展
'The Lock-In™ platform allows our partners to move rapidly from antibody discovery to complex bispecific antibody development,' said
“Lock-In™平台使我们的合作伙伴能够迅速从抗体发现阶段推进到复杂的双特异性抗体开发阶段，”
Gavin Barnard, Ph.D., Chief Scientific Officer (CSO) at ATUM
加文·巴纳德博士，ATUM首席科学官 (CSO)
. 'By maintaining an IgG-like framework, we ensure that the transition from digital monoclonal antibody (mAb) sequences to a high-titer BsAb manufacturing cell line is seamless. By combining with our
“通过保持IgG样的框架，我们确保从数字化单克隆抗体（mAb）序列到高滴度BsAb生产细胞系的过渡是无缝的。通过结合我们的
lightningHEK™ transient expression
lightningHEK™ 瞬时表达
, we can quickly evaluate multiple variable region mAb sequences across various bispecific formats for developability and manufacturability—removing months of development time needed for other formats.'
我们可以快速评估多种双特异性形式的多变量区单克隆抗体序列的可开发性和可制造性，从而节省其他形式所需的数月开发时间。
Technical Snapshot: The Lock-In™ Advantage
技术快照：锁定™ 优势
No Light Chain Mispairing:
无轻链错配：
Eliminates the primary cause of product-related impurities and purification bottlenecks.
消除了与产品相关的杂质和纯化瓶颈的主要原因。
Superior Productivity:
卓越的生产力：
Stable cell lines consistently generate titers exceeding
稳定的细胞系始终产生超过
5 g/L
5 克/升
without evidence of mispairing.
没有错配的证据。
Preserved Potency:
保存的效力：
Avoids the need for common light chains, preserving the original binding affinity and developability of lead candidates.
避免了对共同轻链的需求，保留了先导候选物的原始结合亲和力和可开发性。
Streamlined Purification and Performance
简化纯化与性能
The Lock-In™ platform offers a streamlined path to clinical reality. While traditional methods require extensive 'design-build-test' cycles to address structural instabilities, Lock-In™ enables partners to preserve the integrity of their discovered antibodies while achieving industry-leading expression, purity and stability..
Lock-In™ 平台提供了一条通往临床应用的简化路径。传统方法通常需要进行大量的“设计-构建-测试”循环来解决结构不稳定性问题，而 Lock-In™ 能够帮助合作伙伴在确保其发现的抗体完整性的同时，实现行业领先的表达水平、纯度和稳定性。
For more information, visit
欲了解更多信息，请访问
www.atum.bio
www.atum.bio
.
。
About ATUM
关于ATUM
ATUM is a fully integrated biotechnology contract research organization (CRO) providing services for gene design, protein engineering, and cell line development. By combining machine learning, synthetic biology, and proprietary expression technologies, ATUM helps partners worldwide transform digital sequences into clinical reality.
ATUM是一家完全集成的生物技术合同研究组织（CRO），提供基因设计、蛋白质工程和细胞系开发服务。通过结合机器学习、合成生物学和专有的表达技术，ATUM帮助全球合作伙伴将数字序列转化为临床现实。
ATUM is headquartered in Newark, California..
ATUM总部位于加利福尼亚州纽瓦克。
SOURCE ATUM
来源：ATUM
21
21
%
%
more press release views with
更多新闻发布视图与
Request a Demo
请求演示